{"id":"NCT01152996","sponsor":"Takeda","briefTitle":"Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study","officialTitle":"A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2010-06-29","resultsPosted":"2014-05-28","lastUpdate":"2014-05-28"},"enrollment":1075,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["LuAA21004"]}],"arms":[{"label":"Vortioxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of â‰¥5%","timeFrame":"Over the 52 week period","effectByArm":[{"arm":"Vortioxetine","deltaMin":258,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":1073},"commonTop":["Nausea","Headache","Diarrhea","Vomiting","Nasopharyngitis"]}}